Bioxel Pharma

Bioxel achieves key milestone in manufacturing of docetaxel

Published in Medicine and Law Weekly, October 20th, 2006

Bioxel Pharma, Inc., (BIP) a manufacturer and supplier of taxane APIs and developer of targeted oncology drugs, is pleased to announce manufacturing of the first industrial scale cGMP batch of its key intermediate for docetaxel.

"This achievement is significant for Bioxel's as it clearly demonstrates our ability to manufacture semi-synthetic taxanes using a high-efficiency patent protected route that will allow us to meet the demands of leading pharmaceutical companies" said Pascal Delmas, president and CEO of Bioxel Pharma.

"Bioxel will be sampling its clients with docetaxel API during the fourth quarter of 2006 and we plan to complete the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2006-10-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry